Creo Medical - Observational studies to expand capabilities
Creo Medical has announced a multicentre observational study to assess the safety and efficacy of MicroBlate Flex, a soft tissue microwave ablation device for the treatment of lung lesions. This is the first in human study for the device and is based in the UK, with the potential to expand to up to six sites across Europe and one site in the United States. MicroBlate Flex’s post-market study is one of several planned by Creo (in collaboration with its Kamaptive technology partners) for its ablation devices starting in 2023 and the study aims to generate evidence/user data for the device. We see this development as a positive step towards expanding the market reach of MicroBlate Flex. Recruitment has commenced for the study, with first treatment expected in Q223.Creo Medical Group is a medical device company focused on the field of surgical endoscopy, a recent development in minimally invasive surgery. Co. is focused on developing and commercializing a suite of medical devices based on its CROMA electrosurgery platform.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.